Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Borget

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Thyroid : Official Journal of the American Thyroid Association|January 29, 2015
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohortCecile N Chougnet, Isabelle Borget, Sophie Leboulleux, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2012
A multicenter prospective observational study of the conformity of temozolomide prescriptions in FrancePatrick Tilleul, Melanie Brignone, Yasmine Hassani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2017
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric studyChristophe Massard, Isabelle Borget, Françoise Farace, et al.
Thyroid : Official Journal of the American Thyroid Association|June 23, 2023
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>RAS</i> Mutated Differentiated Thyroid CancerSophie Leboulleux, Daniele Benisvy, David Taieb, et al.
Thyroid : Official Journal of the American Thyroid Association|February 7, 2013
Frequency and intensity of pain related to thyroid nodule fine-needle aspiration cytologySophie Leboulleux, Isabelle Borget, Stéphanie Labro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 12, 2019
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trialBenjamin Lacas, Olivier Bouché, Pierre-Luc Etienne, et al.
Journal of Clinical Epidemiology|July 22, 2017
Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic reviewAnne-France Motte, Stéphanie Diallo, Hélène van den Brink, et al.
The Lancet. Diabetes & Endocrinology|May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trialMartin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|July 16, 2014
Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a reviewElisabeth Mamelle, Isabelle Borget, Sophie Leboulleux, et al.
Annales Pharmaceutiques Francaises|July 12, 2025
Oncology pharmacy practice: Key insights, challenges, and perspectives - A position paper from the French Society for Oncology Pharmacy (SFPO)Florence Ranchon, Florian Slimano, Isabelle Borget, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Thyroid : Official Journal of the American Thyroid Association|January 29, 2015
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohortCecile N Chougnet, Isabelle Borget, Sophie Leboulleux, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2012
A multicenter prospective observational study of the conformity of temozolomide prescriptions in FrancePatrick Tilleul, Melanie Brignone, Yasmine Hassani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2017
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric studyChristophe Massard, Isabelle Borget, Françoise Farace, et al.
Thyroid : Official Journal of the American Thyroid Association|June 23, 2023
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>RAS</i> Mutated Differentiated Thyroid CancerSophie Leboulleux, Daniele Benisvy, David Taieb, et al.
Thyroid : Official Journal of the American Thyroid Association|February 7, 2013
Frequency and intensity of pain related to thyroid nodule fine-needle aspiration cytologySophie Leboulleux, Isabelle Borget, Stéphanie Labro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 12, 2019
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trialBenjamin Lacas, Olivier Bouché, Pierre-Luc Etienne, et al.
Journal of Clinical Epidemiology|July 22, 2017
Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic reviewAnne-France Motte, Stéphanie Diallo, Hélène van den Brink, et al.
The Lancet. Diabetes & Endocrinology|May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trialMartin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|July 16, 2014
Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a reviewElisabeth Mamelle, Isabelle Borget, Sophie Leboulleux, et al.
Annales Pharmaceutiques Francaises|July 12, 2025
Oncology pharmacy practice: Key insights, challenges, and perspectives - A position paper from the French Society for Oncology Pharmacy (SFPO)Florence Ranchon, Florian Slimano, Isabelle Borget, et al.
Pageof 14